APOB and diabetes mellitus: The less atherogenic effect of large chylomicron particles, compared to smaller ApoB100-containing lipoproteins, may be offset by recurrent pancreatitis, leading to diabetes, insulin resistance, and SHTG-induced systemic and vascular inflammation.